Post-metabolic surgery pharmacological adjuvant

Abstract

Treating type 2 diabetes mellitus (T2DM) in patients with obesity remains a challenge for physicians, endocrinologists and surgeons, a fact supported by uncontroverted evidence from studies looking at mortality and associated morbidity. Metabolic surgery remains the most effective treatment for obesity and T2DM. Two important limitations must be recognized and addressed. With regards to long-term remission of T2DM, the metabolic benefits of bariatric surgery appear to fatigue with time and a proportion of patients will not maintain normoglycaemia without pharmacotherapy. Second, there has been noteworthy progress in the development of several classes of medications for the treatment of T2DM. The recognition of the possibility of using pharmacotherapy to improve or maintain CM outcomes presents a new concept in the management of T2DM. The proportion of patients who experience relapse of T2DM does not indicate a failure of CM; rather, it reflects the evolving nature of T2DM. The metabolic benefits of CM may attenuate over time, requiring other interventions such as pharmacotherapy to keep DM2 under control.

Keywords

• obesidad
• diabetes mellitus